A. Scholz

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Scholz, A. Scholz, Arne Scholz
Publication record
118 papers · 3,073 citations · H-index 30

PAPERS

Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model
20231 citationsauthor #8
Abstract 5047: PSMA-targeted actinium-225 conjugate (225Ac-pelgifatamab) potentiates the antitumor efficacy of darolutamide in androgen-dependent and -independent prostate cancer models
20230 citationsauthor #10
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
20235 citationsauthor #11
Targeted thorium-227 conjugates as treatment options in oncology
202327 citationsauthor #5
Abstract 5043: Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer
20232 citationsauthor #1
Safety, tolerability, pharmacokinetics and relative bioavailability of BI 474121 in healthy males – a Phase I study
20221 citationsauthor #3
Abstract 3318: PSMA-targeted thorium-227 conjugate (PSMA-TTC) inhibits tumor growth and abnormal bone changes in the intratibial LNCaP xenograft model of bone-metastatic prostate cancer
20220 citationsauthor #8
Abstract 3311: Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) in a hormone-independent prostate cancer model
20221 citationsauthor #7
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
202143 citationsauthor #14
Synergistic antitumor efficacy of radium-223 and enzalutamide in the intratibial LNCaP prostate cancer xenograft model.
20210 citationsauthor #8
Abstract 1392: Synergistic antitumor efficacy of radium-223 in combination with enzalutamide in the intratibial LNCaP prostate cancer xenograft model
20210 citationsauthor #8
Abstract 1393: PSMA-Targeted Thorium Conjugate (BAY 2315497) and olaparib combination show synergistic anti-tumor activity in prostate cancer models
20212 citationsauthor #6
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
20214 citationsauthor #12
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
202114 citationsauthor #6
Targeting DNA Damage Response in Prostate and Breast Cancer
202065 citationsauthor #2
Abstract 6286: The effects of prednisone, abiraterone acetate and radium-223 dichloride on bone in the intratibial LNCaP prostate cancer model
20202 citationsauthor #8
Abstract 5353: PSMA-targeted thorium conjugate and darolutamide combination show synergistic anti-tumor activity and reduced expression of DNA damage repair genes in prostate cancer models
20200 citationsauthor #7
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy
202054 citationsauthor #8
Abstract 2814: Systemic and local bone metastasis models for immuno-oncology drug development
20190 citationsauthor #5
Abstract 3927: Radium-223 α-particle radiation: Characterization of thein vitroeffects on cancer cells in monotherapy and in combination with DNA repair inhibitors
20190 citationsauthor #3
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
201929 citationsauthor #6
Radium-223 mechanism of action: implications for use in treatment combinations
2019110 citationsauthor #7
The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis
201931 citationsauthor #4
Abstract 3936: Efficacy of single agent radium-223 in the syngeneic MBT-2 bladder cancer bone growth model in mice
20190 citationsauthor #10
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma
201810 citationsauthor #14
Abstract 838: Synergisticin vivoactivity of the ATR inhibitor BAY 1895344 in combination with the targeted alpha therapy radium-223 dichloride in a preclinical tumor model mimicking bone metastatic castration-resistant prostate cancer (mCRPC)
20183 citationsauthor #5
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia
20185 citationsauthor #7
USE OF RADIUM RA-223 CHLORIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
20180 citationsauthor #1
Abstract 4779: Rogaratinib, a small molecule pan-FGFR inhibitor potently inhibits FGFR4-phosphorylation and exerts anti-tumor efficacy in vivo and in vitro
20180 citationsauthor #5
COMBINATION OF ATR KINASE INHIBITORS WITH RADIUM-223 SALT
20180 citationsauthor #2
Abstract 5873: BAY-3827, a selective inhibitor of AMPK for the evaluation of the role of AMPK in Myc-dependent tumors
20181 citationsauthor #12
Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia
201819 citationsauthor #8
Abstract 709: Anti-PD-1 therapy reduces bone lesion growth in a novel syngeneic bladder cancer bone metastasis model
20180 citationsauthor #5
Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops
201716 citationsauthor #2
Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
201760 citationsauthor #16
The Combination of Radium-223 Dichloride and Bortezomib Effectively Reduces Tumor Burden and Lesion Area in the Syngeneic, Systemic 5TGM1 Multiple Myeloma Mouse Model
20170 citationsauthor #14
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
2017152 citationsauthor #15
Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models
20178 citationsauthor #11
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
2017139 citationsauthor #2
Abstract 5202: Additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model
20171 citationsauthor #11
Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)
201613 citationsauthor #1
Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.
20165 citationsauthor #5
Abstract 1722: Hedgehog and Wnt crosstalk in pancreatic cancer
20160 citationsauthor #2
Abstract 2276: Sorafenib/Refametinib potently inhibits Wnt/β-catenin in vitro and patient-derived xenograft models of human hepatocellular carcinoma
20162 citationsauthor #4
Acetyl-CoA carboxylase inhibitors attenuate WNT and Hedgehog signaling and suppress pancreatic tumor growth
201633 citationsauthor #2
Abstract 381: PI3K inhibitor BAY 1082439 and radium-223 dichloride decrease tumor burden and tumor-induced bone formation in an established bone metastatic prostate cancer model in mice
20160 citationsauthor #8
Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback‐Modulation Handles
20152 citationsauthor #4
Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis
20159 citationsauthor #1
Back Cover: Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback‐Modulation Handles (ChemMedChem 12/2015)
20150 citationsauthor #4
Abstract 2828: Rapid identification of potent and highly selective, oral PTEFb Inhibitor BAY 1143572 with first in class potential
20154 citationsauthor #2
Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumour and tumour-induced bone growth in two osteoblastic prostate cancer models
20151 citationsauthor #13
Abstract A109: Radium-223 dichloride inhibits tumor growth and tumor-induced bone growth in osteoblastic prostate cancer models
20151 citationsauthor #8
Abstract 2242: Inhibition of acetyl-CoA carboxylase attenuates lipidation and activity of oncogenic signaling pathways in pancreatic cancer
20150 citationsauthor #2
Abstract 3447: Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models
20151 citationsauthor #13
Validation of In Vitro Cell Viability and Apoptosis Assays for Identifying Compounds that affect Human Multiple Myeloma and Plasma Cell Leukaemia
20150 citationsauthor #8
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
2014125 citationsauthor #11
Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers
20141 citationsauthor #2
Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity
20142 citationsauthor #1
Abstract 4022: Combination of PI3K inhibitor BAY 1082439 with radium-223 is a promising treatment of cancer with bone metastases
20140 citationsauthor #5
63 Radium-223 dichloride – Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis
20140 citationsauthor #11
Derivatives n- (pyridin-2-yl) pyrimidin-4-amine containing sulfoximine group
20130 citationsauthor #3
Abstract 1052: Refametinib (BAY 86-9766): An allosteric inhibitor of MEK1/2, potently inhibits tumor growth in patient-derived xenograft models of gastric cancer.
20130 citationsauthor #5
Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
201387 citationsauthor #10
Abstract 4617: BAY-ACC001, a novel ACC inhibitor, regulates fatty acids synthesis and lipid survival signaling with promisingin vitroandin vivoactivities in multiple preclinical tumor models.
20130 citationsauthor #3
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.
201316 citationsauthor #5
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
201361 citationsauthor #9
Abstract LB-105: Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis.
20131 citationsauthor #10
CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH A SMALL MOLECULE INHIBITOR AND ADP
20130 citationsauthor #5
ADC as therapy response marker for pancreatic ductal adenocarcinoma in genetically engineered mice
20130 citationsauthor #8
Abstract C267: Sequential combination of the novel allosteric MEK1/2 inhibitor BAY 86-9766 (RDEA119) with the mTOR inhibitor rapamycin decelerates relapse of pancreatic tumors.
20130 citationsauthor #3
(5s,8s)-3-(4'-chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-on (verbindung a) zur therapie
20120 citationsauthor #4
Abstract B41: MEK1/2 inhibition with the novel chemotherapeutic agent BAY 86-9766 (RDEA119): A promising treatment strategy for pancreatic cancer.
20120 citationsauthor #3
Abstract 5712: Alpharadin (Radium-223 chloride) completely prevents tumor growth in bone and increases survival in a mouse model of breast cancer bone metastases in preventive and micro-metastatic settings
20124 citationsauthor #7
Abstract 2337: Regorafenib (BAY 73-4506): Anti-metastatic activity in a mouse model of colorectal cancer
20123 citationsauthor #3
959 The MEK Inhibitor BAY 86-9766 Prolongs Survival in Orthotopic, Syngeneic Animal Models of Hepatocellular Carcinoma and Pancreatic Cancer
20120 citationsauthor #6
3-(biphényl-3-yl)-4-hydroxy-8-méthoxy-1-azaspiro[4.5]déc-3-èn-2-one substituée
20120 citationsauthor #4
Derivatives of 5-fluoro-pyrimidine disubstituted containing sulfoximine group
20120 citationsauthor #3
MEK 1 / 2 inhibition with the novel chemotherapeutic agent BAY 86-9766 ( RDEA 119 ) – a promising treatment strategy for pancreatic cancer
20120 citationsauthor #3
Angiopoietin‐2 drives lymphatic metastasis of pancreatic cancer
201177 citationsauthor #14
Abstract A44: 18F-FLT, a potential biomarker for predicting the synergistic combination of PI3K inhibitor BAY 80-6946* and MEK inhibitor BAY 86-9766.
20110 citationsauthor #5
The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer
20116 citationsauthor #4
Abstract 2664: Alpharadin inhibits osteoclast differentiationin vitroand progression of established breast cancer bone metastasesin vivo
20110 citationsauthor #7
Abstract 4262: Regorafenib (BAY 73-4506): A broad spectrum tumor deactivator with high combinability potential and antimetastasis activity
20114 citationsauthor #2
Abstract B247: The MEK inhibitor BAY 869766 inhibits tumor growth and metastatic spread, prolongs the survival and acts synergistically with standard of care drugs in models of hepatocellular carcinoma and pancreatic cancer.
20111 citationsauthor #6
Abstract B3: Allosteric MEK inhibitor BAY 86-9766 acts synergistically with sorafenib to inhibit tumor growth, angiogenesis, and tumor cell survival in ectopic patient-derived xenograft models of human hepatocellular carcinoma.
20110 citationsauthor #3
Abstract 4503: BAY 87-2243, an inhibitor of HIF-1α activation and stabilization, showed promising anti-tumor efficacy either as monotherapy or in combination with anti-VEGF and chemotherapy agents in preclinical tumor models
20112 citationsauthor #6
151 Allosteric MEK inhibitor BAY 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer
20101 citationsauthor #2
138 Combination of PI3K inhibitor BAY 80-6946 with allosteric MEK inhibitor BAY 86-9766 (RDEA119) and with erlotinib for the treatment of non-small cell lung cancer
20103 citationsauthor #4
Angiopoietin-2 Promotes Disease Progression of Neuroendocrine Tumors
201084 citationsauthor #10
140 Combination of PI3K inhibitor BAY 80-6946 and allosteric MEK inhibitor BAY 86-9766 (RDEA119), a promising approach for the treatment of colorectal cancers
20103 citationsauthor #4
Tumor-Associated Angiogenesis and Lymphangiogenesis Correlate With Progression of Intrahepatic Cholangiocarcinoma
201092 citationsauthor #2
Characterization of a new renal cell carcinoma bone metastasis mouse model
201027 citationsauthor #4
Tumor-Associated Lymphangiogenesis Correlates with Prognosis after Resection of Human Hepatocellular Carcinoma
200937 citationsauthor #10
The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model
200837 citationsauthor #1
Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis
200827 citationsauthor #2
S2019 Elevated Serum Ang-2 in Neuroendocrine Tumor Patients Is Associated with Metastatic Spread and Represents a Negative Prognostic Predictor
20080 citationsauthor #4
VEGF‐D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma
200864 citationsauthor #2
Subject Index Vol. 87, 2008
20080 citationsauthor #22
The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer
200884 citationsauthor #3
320 VEGF-D Promotes Tumor Growth and Lymphatic Spread in Hepatocellular Carcinoma
20080 citationsauthor #2

TIMELINE

1996 16 citations

2003 578 citations

2004 143 citations

2005 99 citations

2006 40 citations

2007 81 citations

2008 611 citations

2009 37 citations

2010 210 citations

2011 90 citations

2012 7 citations

2013 165 citations

2014 128 citations

2015 18 citations

2016 53 citations

2017 376 citations

2018 38 citations

2019 170 citations

2020 121 citations

2021 63 citations

2022 2 citations

2023 35 citations

A. Scholz

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT